文献速递垂体与肾上腺疾病性腺与生殖内分泌骨质疏松与钙磷/甲状旁腺

阿那曲唑改善21-羟化酶缺乏症所致先天性肾上腺增生症生长中患儿的身高结局

Anastrozole Improves Height Outcomes in Growing Children With Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

该研究回顾性分析了60例因21-羟化酶缺乏症导致先天性肾上腺增生症(CAH)并接受阿那曲唑治疗的患儿,在8年期间观察骨龄、预测成年身高和身高矫正Z值的变化。结果显示阿那曲唑可降低骨成熟速率并改善身高结局,提示其可能作为CAH伴骨龄提前患儿的辅助治疗。

要点

  • 阿那曲唑治疗4年和6年后,平均骨龄Z值从4.2分别降至2.0和1.3(均P < .001)。
  • 预测成年身高Z值从-2.1分别改善至4年时的-0.45和6年时的0.18(均P < .001)。
  • 身高矫正Z值从-1.7分别改善至4年时的-0.33和6年时的0.18(P < .001)。

核心结论

  • 阿那曲唑减慢了骨成熟速度并改善了身高结局,表明阿那曲唑可能作为CAH伴骨龄提前患儿的辅助治疗。

研究设计与样本

  • 回顾性审查接受阿那曲唑治疗的CAH患者记录,在8年期间检查骨龄、预测成年身高和身高矫正Z值。
  • 共纳入60例患者(26例女性;52例经典型,8例非经典型),开始阿那曲唑治疗。
  • 使用加权混合效应模型分析结局变化,校正性别、诊断、诊断时年龄以及阿那曲唑治疗前后平均氢化可的松剂量。

主要发现

  • 平均骨龄Z值从4.2降至4年时的2.0和6年时的1.3(均P < .001)。
  • 预测成年身高Z值从-2.1改善至4年时的-0.45和6年时的0.18(均P < .001)。
  • 身高矫正Z值从-1.7改善至4年时的-0.33和6年时的0.18(P < .001)。
  • 治疗前与治疗期间的平均每日氢化可的松总剂量无显著差异。

临床怎么用

  • 作者认为阿那曲唑可能作为CAH伴骨龄提前患儿的辅助治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hyperandrogenemia resulting in estrogen-mediated accelerated bone maturation and early growth plate fusion contributes to short stature in children with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. Aromatase inhibitors block androgen conversion to estrogen and have been used off-label in children with short stature to improve adult height. There are no adequately powered studies examining the use of aromatase inhibitors in children with CAH with advanced bone age and reduced predicted adult height. METHODS: Records of CAH patients treated with anastrozole were reviewed. Z-scores of bone age, predicted adult height, and height corrected for bone age were examined over an 8-year period. Outcome changes were analyzed using weighted mixed-effects models, adjusting for sex, diagnosis, age at diagnosis, and average hydrocortisone dose before and during treatment with anastrozole. RESULTS: In 60 patients (26 females; 52 classic, 8 nonclassic) started on anastrozole therapy, the mean bone age Z-score decreased from 4.2 to 2.0 at 4 years and 1.3 at 6 years (both P < .001); predicted adult height Z-score improved from -2.1 to -0.45 at 4 years and 0.18 at 6 years (both P < .001); corrected height Z-scores improved from -1.7 to -0.33 at 4 years and 0.18 at 6 years (P < .001). There was no significant difference in the average total daily hydrocortisone dose used before or during treatment. CONCLUSION: Anastrozole decreased the rate of bone maturation and led to improved height outcomes, indicating that anastrozole could have a role as an adjunct therapy in children with CAH and advanced bone age.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Al-Rayess H, Wiersma R, Turner LE, et al. Anastrozole Improves Height Outcomes in Growing Children With Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency. J Clin Endocrinol Metab. 2025. PMID: 39492684. doi:10.1210/clinem/dgae771

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。